BAJAJ BROKING

Notification close image
No new Notification messages
card image
3B Films IPO is Open!
Apply for the 3B Films IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

HCG Targets 20% Margin in FY26 with Outpatient-Led Oncology Strategy

Synopsis:

HCG is aiming for 20% operating margins in FY26 by shifting focus to outpatient care and strong growth in metro centres. ARPOB has reached Rs.1 lakh in key cities. Q4FY25 margins stood at 17.8% and PAT declined 65.4%.


HealthCare Global Enterprises (HCG) has announced an ambitious target to achieve 20% operating margins in FY26, riding on the strength of its outpatient-driven oncology model and growing revenue from top-performing urban centres. Despite a decline in Q4FY25 margins to 17.8% and a 65.4% drop in profit after tax to Rs.7.36 crore, the company remains focused on delivering consistent long-term growth through higher ARPOB and day-care services.

Also read: IRCON Wins Rs 1,068.3 Cr Rail Bridge EPC Order From East Central Railway

HEALTHCARE GLOB. ENT. LTD

Trade

543.5-5.50 (-1.00 %)

Updated - 03 June 2025
551.50day high
DAY HIGH
542.00day low
DAY LOW
194731
VOLUME (BSE)

Key Takeaways

  • FY26 Margin Target: At least 20%

  • Q4FY25 Operating Margin: 17.8% (vs 18.4% YoY)

  • Q4FY25 PAT: Rs.7.36 crore, down 65.4% YoY

  • Current ARPOB: Around Rs.45,000; growing at 3.5–4% annually

  • Outpatient Contribution: 65–70% of total revenue

  • Expansion Plan: 900 new beds in FY26

  • Urban Centre Growth: Over 40% YoY growth in South Mumbai

Also read: IndiGo Expands A350 Order to 60 Aircraft with Fresh MoU Signed

Operational Highlights

Metric

Value

FY26 Target Margin

20%+

Q4FY25 Margin

17.8%

Q4FY25 PAT

Rs.7.36 crore

ARPOB (Overall)

Rs.45,000

ARPOB (Ahmedabad, Bangalore)

Nearing Rs. 1 lakh

Revenue from Outpatient Services

65–70% of total sales

Planned Bed Addition FY26

900 beds

Urban Centres and Daycare Model Drive Growth

HCG’s strong presence in cities like Mumbai, Bangalore, and Ahmedabad continues to boost its ARPOB and profit potential. Mumbai’s South centre posted over 40% annual growth while the Borivali facility crossed 20% in EBITDA margins. With increasing footfalls and referrals, the company is setting up outpatient infusion centres under a hub-and-spoke model to scale revenue efficiently.

The company is also focused on short-stay treatments, with day chemotherapy and radiation driving most outpatient revenue. While inpatient occupancy may stay flat, the share of outpatient services is expected to grow further.

HCG share price will be watched closely as the company executes its margin expansion strategy. With the KKR acquisition nearing completion, HCG aims to maintain stability in ownership and performance as it pursues sustainable margin growth. The HCG share price closed the previous session lower, but investor interest remains supported by its focused oncology roadmap and urban demand traction.

Also read: Niva Bupa Block Deal: Fettle Tone, Krishnan Ramchandra to Offload 7

Source: CNBCTV18

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|